Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Colorcon
Express Scripts
Baxter
Mallinckrodt

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ASCIMINIB HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Asciminib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03106779 ↗ Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Active, not recruiting Novartis Pharmaceuticals Phase 3 2017-10-26 The purpose of this pivotal study is to compare the efficacy of ABL001 with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of two prior ATP-binding site TKIs. Patients intolerant to the most recent TKI therapy must have BCR-ABL1 ratio > 0.1% IS at screening and patients failing their most recent TKI therapy must meet the definition of treatment failure as per the 2013 ELN guidelines. Patients with documented treatment failure while on bosutinib treatment will have the option to switch to asciminib treatment within 96 weeks after the last patient has been randomized on study.
NCT03578367 ↗ Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Active, not recruiting Novartis Pharmaceuticals Phase 2 2018-11-22 To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP)
NCT03605277 ↗ Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers Completed Novartis Pharmaceuticals Phase 1 2018-11-16 The purpose of this study is to characterize the pharmacokinetics (PK) and safety profile of asciminib following a single oral dose in adult subjects with renal impairment compared to a matched group of healthy subjects with normal renal function. The results will determine whether or not a dose adjustment should be recommended when treating patients with asciminib who have impaired renal function.
NCT03906292 ↗ Frontline Asciminib Combination in Chronic Phase CML Recruiting Ludwig-Maximilians - University of Munich Phase 2 2019-08-19 Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+) and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A <4 week pretreatment with hydroxyurea is permitted. Patients treated for <6 weeks with nilotinib 300 mg BID, imatinib 400 mg QD, dasatinib 100 mg QD or without any therapy are eligible for recruitment and will be allocated to the respective cohort. All patients must provide written informed consent to be enrolled in the trial. Cohorts were designed to allow assessment of QD and BID asciminib based combinations to optimize quality of life and compliance. Patients will not be randomized. In general, cohorts will be filled consecutively. Asciminib therapy will be commenced 12 weeks after start of nilotinib, imatinib or dasatinib and after recovery of hematopoiesis or in case of no therapy so far 6 weeks after diagnosis as first line treatment. Referred patients already treated with imatinib, nilotinib or dasatinib will remain on the initial drug and will be allocated to the respective cohort.
NCT03906292 ↗ Frontline Asciminib Combination in Chronic Phase CML Recruiting Novartis Pharmaceuticals Phase 2 2019-08-19 Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+) and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A <4 week pretreatment with hydroxyurea is permitted. Patients treated for <6 weeks with nilotinib 300 mg BID, imatinib 400 mg QD, dasatinib 100 mg QD or without any therapy are eligible for recruitment and will be allocated to the respective cohort. All patients must provide written informed consent to be enrolled in the trial. Cohorts were designed to allow assessment of QD and BID asciminib based combinations to optimize quality of life and compliance. Patients will not be randomized. In general, cohorts will be filled consecutively. Asciminib therapy will be commenced 12 weeks after start of nilotinib, imatinib or dasatinib and after recovery of hematopoiesis or in case of no therapy so far 6 weeks after diagnosis as first line treatment. Referred patients already treated with imatinib, nilotinib or dasatinib will remain on the initial drug and will be allocated to the respective cohort.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Asciminib Hydrochloride

Condition Name

Condition Name for Asciminib Hydrochloride
Intervention Trials
Chronic Myelogenous Leukemia 4
Chronic Myelogenous Leukemia - Chronic Phase 2
CML 1
Hematologic Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Asciminib Hydrochloride
Intervention Trials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15
Leukemia 13
Leukemia, Myeloid 12
Philadelphia Chromosome 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Asciminib Hydrochloride

Trials by Country

Trials by Country for Asciminib Hydrochloride
Location Trials
United States 24
Spain 9
Japan 7
Germany 6
Italy 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Asciminib Hydrochloride
Location Trials
Texas 3
Illinois 2
Georgia 2
Maryland 2
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Asciminib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Asciminib Hydrochloride
Clinical Trial Phase Trials
Phase 3 7
Phase 2 7
Phase 1/Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Asciminib Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 7
Recruiting 6
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Asciminib Hydrochloride

Sponsor Name

Sponsor Name for Asciminib Hydrochloride
Sponsor Trials
Novartis Pharmaceuticals 12
H. Jean Khoury Cure CML Consortium 2
Sarit Assouline 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Asciminib Hydrochloride
Sponsor Trials
Industry 13
Other 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Merck
Dow
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.